Below is a list of the 20 most expensive prescription drugs in the U.S., based on the official price their manufacture assigned to them, as compiled by prescription discount company GoodRx. This list excludes medications that must be administered by a healthcare practitioner.
- Zokinvy (Eiger BioPharmaceuticals): $86,040
- Myalept (Aegerion Pharmaceuticals): $74,159
- Mavenclad (EMD Serono): $60,371
- Ravicti (Horizon Therapeutics): $57,998
- Actimmune (Horizon Therapeutics): $55,310
- Oxervate (Dompé): $48,498
- Takhzyro (Takeda): $46,828
- Juxtapid (Aegerion Pharmaceuticals): $46,502
- Cinryze (Takeda): $45,465
- Chenodal (Travere Therapeutics): $42,570
- Gattex (Takeda): $41,664
- H.P. Acthar (Mallinckrodt Pharmaceuticals): $39,864
- Orladeyo (BioCryst Pharmaceuticals): $37,308
- Tegsedi (Akcea Therapeutics): $35,638
- Ayvakit (Blueprint Medicines): $33,568
- Vitrakvi (Bayer Pharmaceuticals): $32,800
- Qinlock (Decipera Pharmaceuticals): $32,000
- Korlym (Corcept Therapeutics): $31,440
- Cerdelga (Genzyme): $28,599
- Idhifa (Celgene): $28,246
More articles on pharmacy:
J&J submits FDA application for COVID-19 vaccine
Pentagon to deploy troops to help with COVID-19 vaccine administration
AstraZeneca’s vaccine may not effectively protect against South Africa variant, small trial shows
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
